IRCT20100228003449N30
Recruiting
Phase 2
Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir/ritonavir combination in patients with COVID-19
ConditionsCOVID-19 pneumonia.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19 pneumonia.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with highly suspected or confirmed COVID\-19 who are candid for hospitalization and starting triple\-drug combination
Exclusion Criteria
- •History of drug allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N20Ardabil University of Medical Sciences100
Completed
Phase 3
Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19IRCT20200318046812N1Iran University of Medical Sciences324
Recruiting
Phase 3
Treatment of Hydroxychloroquine in Type 2 Diabetes Patients Uncontrolled on Metformin MonotherapyHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2021/11/037750Ipca Laboratories Ltd
Recruiting
Phase 3
Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxisCOVID-19 pneumonia.COVID-19, virus not identifiedU07.2IRCT20130917014693N10Shahid Beheshti University of Medical Sciences100
Recruiting
Phase 4
A Clinical Trial to Study the Safety and Efficacy of Hydroxychloroquine in Patients with Type-2 DaibetesHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complicationsCTRI/2016/02/006599Ipca Laboratories Ltd600